Sesame Summit 2026 – application open

Rivia raises €13M to scale agentic AI platform for clinical trials

The application of artificial intelligence in clinical trials is rapidly reshaping how the pharmaceutical and biotech industries manage the vast, fragmented data sets that underpin drug development. With clinical trial data volumes having grown by more than 400 per cent over the past decade, the need for intelligent infrastructure capable of unifying and analysing this information has never been more pressing. Zurich-based startup Rivia has raised €13 million in a Series A round to expand its agentic AI data platform, positioning itself at the forefront of this transformation.

The round was led by Earlybird, one of Europe’s most established venture capital firms, with Defiant joining as a new investor alongside existing backers Speedinvest, Amino Collective, and Nina Capital. The fresh capital will support product development, team expansion, and international growth, with a particular focus on the US biotech market as demand for more efficient trial execution continues to accelerate.

Earlybird leads Series A as agentic AI gains traction in healthcare

Founded in 2022 by Erik Scalfaro and Tiago Kieliger, Rivia has built what it describes as an agentic data engine — a system in which AI agents actively surface insights, flag anomalies, and help coordinate the operational layer of a clinical trial, rather than simply storing and visualising data. The platform comprises three core components: Rivia Core, which consolidates fragmented data from thousands of heterogeneous files across vendors into a structured foundation; Rivia Detect, which continuously monitors data quality, clusters thousands of issues, and automates corrective actions; and Rivia Spark, which transforms natural language queries into visual analytics for patient cohorts, adverse events, and biomarkers.

The company currently supports approximately 40 clinical trials across Europe and the United States, integrating data from specialty laboratories, patient wearables, genomics platforms, and imaging systems into a single, harmonised infrastructure. Erik Scalfaro, CEO and co-founder of Rivia, has spoken about the company’s deliberate approach to building its technology, noting that Rivia started with the foundational data engine before layering in agentic capabilities — a sequence he believes gives the company a structural advantage over competitors.

AI in clinical trials market poised for significant growth

The global AI in clinical trials market is estimated at approximately $2.09 billion in 2026 and is projected to reach $18.62 billion by 2040, reflecting a compound annual growth rate of 17 per cent. Industry analysts anticipate that AI-driven solutions could reduce clinical development timelines by 30 to 40 per cent within the next two to five years, a prospect that is drawing considerable investor attention to the space.

Rivia’s focus on agentic AI — where autonomous agents manage workflows from data integration to real-time risk monitoring — places it within one of the fastest-growing segments of health technology. Unlike traditional clinical data management systems that require extensive manual intervention, agentic platforms can proactively identify protocol deviations, predict enrolment bottlenecks, and automate regulatory reporting workflows. This shift from passive data storage to active intelligence represents a fundamental change in how trials are operated.

The Series A round follows a €3 million seed round in 2024, also backed by Speedinvest, Amino Collective, and Nina Capital. With the European clinical trial ecosystem increasingly competing for global biotech investment, platforms like Rivia that bridge European innovation with US market access are well positioned to capture growing demand for next-generation trial infrastructure.

Summary

Company: Rivia
Headquarters: Zurich, Switzerland
Founded: 2022
Founders: Erik Scalfaro (CEO), Tiago Kieliger
Round: Series A
Amount: €13 million (~$15 million)
Lead investor: Earlybird
Other investors: Defiant, Speedinvest, Amino Collective, Nina Capital
Use of funds: Product development, team growth, US market expansion

you might also like

Fundraising 4 hours ago

London-based AI laboratory Ineffable Intelligence has emerged from stealth with a $1.1 billion seed round at a $5.1 billion post-money valuation, the company confirmed on 27 April 2026. The financing is the largest seed round ever raised by a European company and one of the largest first-money-in rounds in the global history of artificial intelligence. The round was co-led by Sequoia Capital and Lightspeed Venture Partners. Participating investors included Nvidia, DST Global, Index Ventures, Google, and the UK Sovereign AI Fund, the British government’s recently established vehicle for backing strategic AI capacity on home soil. A bet on a different path to general intelligence Ineffable Intelligence was founded in 2025 by David Silver, the former Vice President of Reinforcement Learning at Google DeepMind and the principal architect of AlphaGo, AlphaZero and AlphaStar. He is joined by three further DeepMind alumni: Wojciech Czarnecki, Lasse Espeholt and Junhyuk Oh. All four have spent the past decade at the frontier of reinforcement learning research, the discipline behind some of the most consequential demonstrations of machine learning over the past ten years. The company describes its objective as building a “superlearner” — an AI system capable of acquiring knowledge directly from its own experience rather than from human-generated text or imagery. “Our mission is to make first contact with superintelligence,” Silver said in a statement accompanying the launch. “We are creating a superlearner that discovers all knowledge from its own experience, from elementary motor skills through to profound intellectual breakthroughs.” The framing is a deliberate departure from the dominant industry trajectory. Most leading AI laboratories, including OpenAI, Anthropic and Google DeepMind itself, have built large language models trained primarily on the corpus of the internet, then refined that training with human feedback. Ineffable’s wager is that the marginal returns on scaling text-based pretraining are diminishing and that the next leap in capability will come from agents that learn endlessly from the consequences of their own actions, in much the same way AlphaZero learnt the game of Go without studying any human matches. Why $1.1 billion at seed The size of the round is unusual even by the inflated standards of the 2026 AI capital cycle. Two factors appear to explain it. First, frontier reinforcement learning at the scale Ineffable describes is computationally extraordinarily expensive: the company will need to operate vast simulation environments and train very large models against them, an undertaking that consumes capital at a rate closer to physical R&D than to traditional software. Second, the round signals a strategic move by Europe’s investor and policy ecosystems to retain the most ambitious AI researchers on the continent. The presence of the UK Sovereign AI Fund alongside Sequoia, Lightspeed and Nvidia is the clearest expression of that intent. The British government has publicly framed the investment as a bet on breakthrough AI that “can discover new knowledge”, positioning the country as a willing co-investor in domestic frontier laboratories. For Ineffable, the implication is access not only to capital but to compute, regulatory engagement and the still-resilient academic talent base around UCL, Oxford, Cambridge and Imperial. Founder pledge of historic scale Alongside the funding announcement, Silver disclosed that he is committing 100 per cent of any personal proceeds from his Ineffable equity to charity via the Founders Pledge network — described by the organisation as the largest pledge in its history. At the round’s $5.1 billion valuation, that commitment could ultimately exceed several billion dollars if the company succeeds. It is a meaningful gesture in a sector where the reputational stakes around concentrated AI wealth are escalating, and one likely to be referenced in subsequent founder-led commitments. Implications for the European AI landscape Ineffable’s emergence reshapes the European AI map in three concrete ways. It establishes London as the home of the continent’s largest-ever seed-stage company, complicating Paris’s recent narrative of frontier-AI primacy after Mistral’s earlier rounds. It validates a thesis — that reinforcement learning, not transformer scaling, is the next frontier — that has lately been losing capital share to language-model incumbents. And it confirms that the UK government is now willing to act as a balance-sheet co-investor in domestic AI laboratories, a posture much closer to the French model than to the predominantly grant-based regimes elsewhere in Europe. The execution risk is non-trivial. Reinforcement learning at frontier scale has historically required years of careful environment design before producing competitive systems, and Ineffable’s “first contact” framing sets a high bar against which it will be judged. But for now, with a billion dollars on the balance sheet, four of the discipline’s most accomplished researchers in the founding team and a sovereign co-investor at its back, Ineffable Intelligence is the most heavily resourced new entrant in the European AI cycle. Sesamers covers European fundraising rounds across deeptech, fintech and AI. Source: tech.eu.

Fundraising 5 days ago

Belfast's Cloudsmith has raised $72M Series C led by TCV, with Insight Partners participating, to expand its artifact management platform and secure the AI-era software supply chain.

Fundraising 5 days ago

Berlin’s VREY has raised €3.3M seed led by Rubio Impact Ventures to roll out rooftop solar software for Germany’s multi-family buildings.

Subscribe to
our Newsletter!

Stay at the forefront with our curated guide to the best upcoming Tech events.